What service do you need? Contact Request

NCT07865377

Serum Endogenous Estrogens, Estrogen Receptors, and Sirtuin-1 and -3 After Resveratrol Supplementation

← Clinical trials hub

Registry fields

Overall status: RECRUITING
Conditions: Coronary Artery Disease (CAD), Menopause, Hormones
Study type: INTERVENTIONAL
Phase: NA
Primary purpose: PREVENTION
Intervention type: DIETARY_SUPPLEMENT, OTHER
Interventions: Trans-resveratrol, 1000 mg daily for 90 days, Placebo
Lead sponsor: InCor Heart Institute (OTHER)

Cached at: 2026-10-09 02:19:05

View on ClinicalTrials.gov

Brief summary

Atherosclerotic coronary artery disease (CAD) is a leading cause of mortality among postmenopausal women. Resveratrol, a phenolic compound with antioxidant properties, may influence lipid metabolism, endothelial function, and platelet aggregation, while sirtuin-1 and sirtuin-3 regulate metabolic and hormonal responses to nutritional stimuli. This randomized, double-blind, placebo-controlled trial evaluates the effects of trans-resveratrol supplementation (1000 mg/day) versus placebo, over 90 days, on serum estradiol and estrone levels, gene expression of estrogen receptors alpha and beta, and sirtuins 1 and 3 in 80 postmenopausal women with CAD. Findings may inform therapeutic strategies for postmenopausal women with chronic coronary disease.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report